BTK
Les inhibiteurs de la tyrosine kinase de Bruton (BTK) sont des composés qui ciblent spécifiquement et inhibent la BTK, une enzyme cruciale impliquée dans la signalisation du récepteur des cellules B et la régulation de l'angiogenèse. La BTK joue un rôle significatif dans la prolifération et la survie des cellules cancéreuses, en particulier dans les malignités hématologiques. En inhibant la BTK, ces composés peuvent perturber l'angiogenèse et la croissance tumorale, ce qui les rend précieux en thérapie anticancéreuse. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de la BTK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
166 produits trouvés pour "BTK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
UBX-382
CAS :UBX-382 is an orally administered proteolysis-targeting chimera (PROTAC) designed to target BTK and disrupt B-cell receptor signaling. It demonstrates enhanced degradation of both wild-type and mutant BTK proteins, exhibiting anti-cancer effects in murine xenograft models using TMD-8 cells [1].Formule :C42H44N10O4Couleur et forme :SolidMasse moléculaire :752.86BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formule :C28H24FN5O2Couleur et forme :SolidMasse moléculaire :481.52BTK-IN-32
CAS :BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Formule :C35H35ClN4O3SCouleur et forme :SolidMasse moléculaire :627.2RET-IN-14
CAS :RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.Formule :C24H23FN8O4Couleur et forme :SolidMasse moléculaire :506.49G-744
CAS :G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).Formule :C29H29N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :527.64TQ-3959
CAS :TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Formule :C40H47N11O5Couleur et forme :SolidMasse moléculaire :761.87(Rac)-Ibrutinib alkyne
CAS :(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Formule :C25H22N6O2Couleur et forme :SolidMasse moléculaire :438.48BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Formule :C26H36N6O3Couleur et forme :SolidMasse moléculaire :480.6BTK-IN-34
CAS :BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Formule :C22H29N3O4SCouleur et forme :SolidMasse moléculaire :431.55HDHD4-IN-1
CAS :HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Formule :C12H22NO11PCouleur et forme :SolidMasse moléculaire :387.28BTK-IN-10
CAS :BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Formule :C25H24F2N4O2Couleur et forme :SolidMasse moléculaire :450.48Ibrutinib Racemate
CAS :Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formule :C25H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.5Dihydrodiol-Ibrutinib
CAS :PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formule :C25H26N6O4Couleur et forme :SolidMasse moléculaire :474.521JDB175
CAS :JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.
Formule :C26H21F3N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :478.47BTK-IN-25
CAS :BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].
Formule :C28H27F2N3O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :523.53BTK-IN-27
CAS :BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.
Formule :C31H35N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :537.66
